Luteolin inhibits proliferation induced by IGF-1 pathway dependent ERα in human breast cancer MCF-7 cells

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 4, 2012, Pages 1431-1437

  Wang, Li Meng ^a   Xie, Kun Peng ^a   Huo, Hong Nan ^a   Shang, Fei ^a   Zou, Wei ^a   Xie, Ming Jie ^a  

^a LIAONING NORMAL UNIVERSITY   (China)

Author keywords

Breast cancer; Er ; Igf 1; Luteolin; Mcf 7

Indexed keywords

ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR ALPHA; LUTEOLIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR;

APOPTOSIS; ARTICLE; CELL CYCLE CHECKPOINT; CELL PROLIFERATION; CELL STRAIN MCF 7; CELL SURVIVAL; DRUG EFFECT; HUMAN; METABOLISM; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANTICARCINOGENIC AGENTS; APOPTOSIS; CELL CYCLE CHECKPOINTS; CELL PROLIFERATION; CELL SURVIVAL; ESTROGEN RECEPTOR ALPHA; HUMANS; INSULIN-LIKE GROWTH FACTOR I; LUTEOLIN; MAP KINASE SIGNALING SYSTEM; MCF-7 CELLS; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION;

EID: 84873036300     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.4.1431     Document Type: Article

References (43)

1. Baselga J, Campone M, Piccart M, et al (2012). Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med, 366, 520-9.
2. Baselga J, Cortes J, Kim SB, et al (2012). Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med, 366, 109-19.
3. Baserga R (2009). Customizing the targeting of IGF-1 receptor. Future Oncol, 5, 43-50.
4. Bustin SA, Dorudi S, Phillips SM, et al (2002). Local expression of insulin-like growth factor-I affects angiogenesis in colorectal cancer. Tumor Biol, 23, 130-8.
5. Berrino F, De AR, Sant M, et al (2007). Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-1999: results of the EUROCARE-4 study. Lancet Oncol, 8, 773-83.
6. Buck E, Gokhale PC, Koujak S, et al (2010). Compensatory insulin receptor (IR) activatio on inhibition of insulin-like growth factor-1 receptor (IGF-IR): rationale for cotargeting IGF-1R and IR in cancer. Mol Cancer Ther, 9, 2652-64.
7. Buck E, Mulvihill M (2011). Small molecule inhibitors of the IGF-1R/IR axis for the treatment of cancer. Expert Opin Investig, 20, 605-21.
8. Castoria G, Migliaccio A, Bilancio A, et al (2001). PI3-kinase in concert with Src promotes the S-phase entry of estradiol- stimulated MCF-7 cells. EMBO J, 20, 6050-9.
9. Carboni JM, Lee AV, Had sell DL, et al (2007). Tumor development by transgenic expression of a constitutively active insulin - like growth factor I recep tor. Cancer Res, 65, 3781-7.
10. Dong RY, Yun HJ, Yeong KJ, et al (2009). Proteomic identification of anti-cancer proteins in luteolin-treated human hepatoma Huh-7 cells. Cancer Lett, 282, 48-54.
11. Dong S, Akio I, Yun Z, et al (2007). Activation of rapid signaling pathways and the subsequent transcriptional regulation for the proliferation of breast cancer MCF-7 cells by the treatment with an extract of Glycyrrhiza glabra root. Food Chem Toxicol, 45, 2470-8.
12. Du GJ, Song ZH, Lin HH, et al (2008). Luteolin as a glycolysis inhibitor offers superior efficacy and lesser toxicity of doxorubicin in breast cancer cells. Biochem Biophys Res Commun, 372, 497-502.
13. Fagan DH, Yee D (2008). Crosstalk between IGF1R and estrogen receptor signaling in breast cancer. J Mammary Gland Biol Neoplasia, 13, 423-9.
14. Fang J, Zhou Q, Shi XL, et al (2007). Luteolin inhibits insulin-like growth factor 1 receptor signaling in prostate cancer cells. Carcinogenesis, 28, 713-23.
15. Gualberto A, Poliak M (2009). Clinical development of inhibitors of the insulin-like growth factor receptor in oncology. Curr Drug Targets, 10, 923-36.
16. Hou YN, Wu JC, Huang Q, et al (2009). Luteolin inhibits proliferation and affects the function of stimulated rat synovial fibroblasts. Cell Biol Int, 33, 135-47.
17. Jemal A, Siegel R, Ward E, et al (2011). Cancer Stat CA Cancer J Clin, 61, 69-90.
18. Kahlert S, Nuedling S, van Eickels M, et al (2000). Estrogen receptor alpha rapidly activates the IGF-1 receptor pathway JBiol Chem, 275, 18447-53.
19. Kappel CC, Velez-Yanguas MC, Hirschfeld S, et al (1994). Human osteosarcoma cell lines are dependent on insulin-like growth factor I for in vitro growth. Cancer Res, 54, 2803-7.
20. Klotz DM, Hewitt SC, Ciana P, et al (2002). Requirement of estrogen receptor-alpha in insulin-like growth factor-1(IGF- 1)-induced uterine responses and in vivo evidence for IGF-1/ estrogen receptor cross-talk. JBiol Chem, 277, 8531-7.
21. Law JH, Habibi G, Hu K, et al (2008). Phosphorylated insulin-like growth factor-I/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res, 68, 10238-46.
22. Lin Y, Shi R, Wang X, et al (2008). Luteolin, a flavonoid with potential for cancer prevention and therapy. Curr Cancer Drug Targets, 8, 634-46.
23. Oesterreich S, Zhang P, Guler RL, et al (2001). Re-expression of estrogen receptor a in estrogen receptor a-negative MCF-7 cells restores both estrogen and insulin-like growth factorfactor-mediated signaling and growth. Cancer Res, 61, 5771-7.
24. Pollak M (2008). Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer, 8, 915-28.
25. Ren WY, Qiao ZH, Wang HW, et al (2003). Flavonoids: Promising AnticancerAgents. MedResRev, 23, 519-34.
26. Resnicoff M, Abraham D, Yutanawiboonchai W, et al (1995). The insulin-like growth factor 1 receptor protects tumor cells from apoptosis in vivo. Cancer Res, 55, 2463-9.
27. Sachdev D, Yee D (2001). The IGF system and breast cancer. Endocrine-Related Cancer, 8, 197-209. Sachdev D, Yee D (2001). The IGF system and breast cancer. Endocr Relat Cancer, 8, 197-209.
28. Sachdev D, Yee D (2001). The IGF system and breast cancer. Endocr Relat Cancer, 8, 197-209.
29. Sachdev D, Yee D (2007). Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther, 6, 1-12.
30. Salerno M, Sisci D, Mauro L, et al (1999). Insulin receptor substrate lisa target for the pure antiestrogen ICI 182,780 in breast cancer cells. IntJCancer, 81, 299-304.
31. Sarfstein R, Pasmanik-Chor M, Yeheskel A, et al (2012). The insulin-like growth factor-I receptor (IGF-IR) translocates to the nucleus and autoregulates IGF-1R gene expression in breast cancer cells. J Biol Chem, 287, 2766-76.
32. Sogno I, Vene R, Ferrari N, et al (2010). Angioprevention with fenretinide: targeting angiogenesis in prevention and therapeutic strategies. CritRev Oncol Hematol, 75, 2-14.
33. Surmacz E (2002). Function of the IGF-1 receptor in breast cancer. J Mammary Glnad Biol Neoplasia, 5, 95.
34. Surmacz E, Bartucci M (2004). Role of estrogen receptor alpha in modulating IGF-I receptor signaling and function in breast cancer. J Exp Clin Cancer Res, 23, 385-94.
35. Vera-Ramirez L, Sanchez-Rovira P, Ramirez-Trtosa MC, et al (2011). Free radicals in breast carcinogenesis, breast cancer progression and cancer stem cells. Biological bases to develop oxidative-based therapies. Crit Rev Oncol Heamtol, 80, 347-68.
36. Wang ZF, Cui MB, Song FR, et al (2008). Evaluation of flavonoids binding to DNA duplexes by electrospray ionization mass spectrometry. J Am Soc Mass Spectrom, 19, 914-22.
37. Werner H, LeRoith D (2000). New concepts in regulation of the insulin-like growth factors: implication for understanding normal growth and neoplasia. CellMol, 57, 932-42.
38. Weroha SJ, Haluska P (2008). IGF-1 receptor inhibitors in clinical trials-early lessons. J Mammary Gland Biol, 13, 471-83.
39. Xia Y, Jin L, Zhang B, et al (2007). The potentiation of curcumin on insulin-like growth factor-1 action in MCF-7 human breast carcinoma cells. Life Sci, 80, 2161-9. Yuen JS, Macaulay VM (2008). Targeting the type 1 insulin-like growth factor receptor as a treatment for cancer. Expert Opin Ther Targets, 12, 589-603.
40. Yuen JS, Macaulay VM (2008). Targeting the type 1 insulin-like growth factor receptor as a treatment for cancer. Expert Opin Ther Targets, 12, 589-603.
41. Zha J, O'Brien C, Savage H, et al (2009). Molecular predictors of response to a humanized anti-insulin-like growth factor-I receptor monoclonal antibody in breast and colorectal cancer. Mol Cancer Ther, 8, 2110-21.
42. Zhang S, Li X, Burghardt R, et al (2005). Role of estrogen receptor (ERa) in insulin-like growth factor (IGF) -I-induced responses in MCF-7 breast cancer cells. J Mol Endocrinol, 35, 433-47.
43. Zhu C, Qi X, Chen Y, et al (2011). PI3K/Akt and MAPK/ ERK1/2 signaling pathways are involved in IGF-1-induced VEGF-C upregulation in breast cancer. J Cancer Res Clin Oncol, 137, 1587-94.